{
    "clinical_study": {
        "@rank": "127918", 
        "acronym": "ARUMM", 
        "arm_group": [
            {
                "arm_group_label": "Lenalidomide", 
                "arm_group_type": "Experimental", 
                "description": "Treatment Arm A: lenalidomide 10 mg/day orally from Days 1 to 21; given in 28-day cycles for up to disease progression."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Treatment Arm B: placebo orally from Days 1 to 21; given in 28-day cycles for up to disease progression."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the safety and efficacy of Lanalidomide versus\n      Placebo maintenance following melphalan, prednisone and velcade induction therapy in newly\n      diagnosed multiple myeloma."
        }, 
        "brief_title": "Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade\u00ae Induction Therapy in NDMM", 
        "completion_date": {
            "#text": "June 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must meet all of the following inclusion criteria to be eligible for\n             enrollment into the study:\n\n        Related to initial diagnosis and prior Melphalan Prednisone Velcade (MPV) induction\n        therapy\n\n          1. Previously untreated and symptomatic multiple myeloma.\n\n          2. All 3 criteria (Durie, 2003) and at least one of the Creatinine Renal insufficiency\n             Anemia lytic Bone lesions or osteoporosis criteria must be met.\n\n          3. Measurable disease by protein electrophoresis analyses.\n\n          4. All subjects must be treated with a minimum of 6 and a maximum of 9 cycles of MPV\n             induction regimen, and must have achieved at least Partial Response as best overall\n             response and maintained at Melphalan Predinisone Velcade discontinuation. If a\n             subject achieves Complete Response prior to at least 6 cycles, the subject will be\n             eligible, but a minimum of 6 cycles must be administered otherwise.\n\n          5. Subjects must not have received any prior anti-myeloma chemotherapy or any\n             investigational agent except 6-9 cycles of induction therapy with Melphalan\n             Predinisone Velcade.\n\n          6. Subjects must have cytogenetic (17 p deletion, and 4;14 translocation), \u03b2-2\n             microglobulin and serum albumin (International Staging System) results from their\n             initial diagnosis available at the time of  screening.\n\n             Related to the subject\n\n          7. Must understand and voluntarily sign the informed consent document prior to the\n             conduct of any study related assessments/procedures,\n\n          8. Age \u2265 65 years: if < 65 years of age, the subject must be non eligible for stem cell\n             transplantation,\n\n          9. Eastern Cooperative Oncology Group performance status score \u2264 2,\n\n         10. Able to adhere to the study visit schedules and other protocol requirements,\n\n         11. Females of Childbearing Potential must:\n\n               1. Have two negative pregnancy tests as verified by the study doctor prior to\n                  starting study therapy. She must agree to ongoing pregnancy testing during the\n                  course of the study, and after the end of study therapy. This applies even if\n                  the subject practices true abstinence2 from heterosexual contact.\n\n               2. Either commit to true abstinence from heterosexual contact (which must be\n                  reviewed on a monthly basis) or agree to use, and be able to comply with,\n                  effective contraception without interruption, 28 days prior to starting\n                  Investigational Product, during the study therapy (including dose\n                  interruptions), and for 28 days after discontinuation of study therapy.\n\n         12. Male Subjects must:\n\n               1. Practice true abstinence or agree to use a condom during sexual contact with a\n                  pregnant female or a female or childbearing potential while participating in the\n                  study, during dose interruptions and for at least 28 days following\n                  Investigational Product discontinuation, even if he has undergone a successful\n                  vasectomy.\n\n               2. Agree to not donate semen during Investigational Product therapy and for 28 days\n                  after end of study therapy.\n\n         13. All subjects must:\n\n               1. Have an understanding that the study medication could have a potential\n                  teratogenic risk.\n\n               2. Agree to abstain from donating blood while taking Investigational Product\n                  therapy and following discontinuation of Investigational Product therapy.\n\n               3. Agree not to share study medication with another person.\n\n               4. All female of childbearing potential and male subjects must be counseled about\n                  pregnancy precautions and risks of fetal exposure.\n\n        Exclusion Criteria:\n\n          -  The presence of any of the following will exclude the subject from the study\n             enrollment:\n\n               1. Previous treatment with anti-myeloma therapy other than the required 6-9 cycles\n                  of Melphalan Prednisone Velcade induction therapy (does not include local\n                  radiotherapy, bisphosphonates, or a single short course of steroid [ie, less\n                  than or equal to the equivalent of dexamethasone 40 mg/day for 4 days; such a\n                  short course of steroid treatment must not have been given within 14 days of\n                  randomization]).\n\n               2. Subjects who didn't achieve Partial Response or better after getting at least 6\n                  cycles of Melphalan Predinisone Velcade and at the end of Melphalan Prednisone\n                  Velcade whatever the overall response are not eligible.\n\n               3. Prior therapy with immunomodulating or immunosuppressive agents, or epigenetic\n                  or desoxyribonucleic acid modulating agents. Subjects who received\n                  investigational agents are also excluded.\n\n               4. Any significant medical condition, laboratory abnormality, or psychiatric\n                  illness that would prevent the subject from participating in the study.\n\n               5. Any condition including the presence of laboratory abnormalities, which places\n                  the subject at unacceptable risk if he/she were to participate in the study\n\n               6. Pregnant or lactating females.\n\n               7. Any of the following laboratory abnormalities:\n\n                  Absolute neutrophil count < 1,000/L (1.0 x 10*9/L) Untransfused platelet count <\n                  50,000 cells/L (50 x 10*9/L) Serum glutamic oxaloacetic transaminase/alanine\n                  aminotransferase or serum glutamic pyruvic transaminase/alanine aminotransferase\n                  > 3.0 x upper limit of normal Serum bilirubin levels > 1.5 x upper limit of\n                  normal\n\n               8. Renal insufficiency (creatinine clearance < 30 mL/min by Cockroft-Gault method)\n                  or actual creatinine clearance result, or renal failure requiring hemodialysis\n                  or peritonela dialysis.\n\n               9. Prior history of malignancies including skin cancer, other than multiple\n                  myeloma.\n\n              10. Prior history of deep venous thrombosis or pulmonary embolus within 3 years of\n                  randomization.\n\n              11. Subjects who are unable or unwilling to undergo anti-thrombotic therapy.\n\n              12. Peripheral neuropathy of > Grade 2 severity according to the National Cancer\n                  Institute Common Terminology Criteria for Adverse Events Version 4.0.\n\n              13. Known Human Immunodeficiency Virus positivity or active infectious hepatitis,\n                  type A, B, or C.\n\n              14. Primary amyloidosis (immunoglobulin light chain) and myeloma complicated by\n                  amyloidosis.\n\n              15. Prior allogeneic or autologous stem cell transplantation.\n\n              16. Significant active cardiac disease within the previous 6 months including:\n\n                  New York Heart Association class II-IV congestive heart failure Unstable angina\n                  or angina requiring surgical or medical intervention Myocardial infarction\n\n              17. Any condition that confounds the ability to interpret data from the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "351", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02112175", 
            "org_study_id": "CC-5013-MM-026"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lenalidomide", 
                "intervention_name": "Lenalidomide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Melphalan", 
                "Lenalidomide", 
                "Prednisone", 
                "Thalidomide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Multiple Myeloma", 
            "Lenalidomide", 
            "Revlimid", 
            "MPV", 
            "Melphalan", 
            "Prednisone", 
            "Velcade", 
            "Placebo"
        ], 
        "lastchanged_date": "April 9, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Yvoir", 
                        "country": "Belgium", 
                        "zip": "B-5530"
                    }, 
                    "name": "CHU UCL Montgodinne-Dinant"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amiens", 
                        "country": "France", 
                        "zip": "80054"
                    }, 
                    "name": "CHU d'Amiens - H\u00f4pital Sud"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bayonne", 
                        "country": "France", 
                        "zip": "64109"
                    }, 
                    "name": "Centre Hospitalier de la C\u00f4te Basque"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Besan\u00e7on Cedex", 
                        "country": "France", 
                        "zip": "25030"
                    }, 
                    "name": "CHU de Besancon - H\u00f4pital Jean Minjoz"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "zip": "33300"
                    }, 
                    "name": "Polyclinique Bordeaux Nord Aquitaine"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bourg en Bresse Cedex", 
                        "country": "France", 
                        "zip": "01012"
                    }, 
                    "name": "Hopital de Fleyriat"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Caen Cedex 9", 
                        "country": "France", 
                        "zip": "14033"
                    }, 
                    "name": "CHU de Caen - H\u00f4pital C\u00f4t\u00e9 de Nacre"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Creteil", 
                        "country": "France", 
                        "zip": "94010"
                    }, 
                    "name": "H\u00f4pital Henri Mondor"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dunkerque", 
                        "country": "France", 
                        "zip": "59385"
                    }, 
                    "name": "Centre Hospitalier de Dunkerque"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "La Roche sur Yon Cedex 9", 
                        "country": "France", 
                        "zip": "85925"
                    }, 
                    "name": "Centre Hospitalier D\u00e9partemental site de la Roche-sur-Yon"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Le Chesnay", 
                        "country": "France", 
                        "zip": "78157"
                    }, 
                    "name": "H\u00f4pital Andr\u00e9 Mignot"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Le Kremlin Bic\u00eatre Cedex", 
                        "country": "France", 
                        "zip": "94275"
                    }, 
                    "name": "H\u00f4pital Kremlin Bic\u00eatre"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille Cedex", 
                        "country": "France", 
                        "zip": "59037"
                    }, 
                    "name": "CHRU-Hopital Claude Huriez"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nantes Cedex 01", 
                        "country": "France", 
                        "zip": "44093"
                    }, 
                    "name": "CHU De Nantes Hotel-Dieu"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nimes", 
                        "country": "France", 
                        "zip": "30029"
                    }, 
                    "name": "CHU Nimes"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pessac", 
                        "country": "France", 
                        "zip": "33604"
                    }, 
                    "name": "CHRU - H\u00f4pital du Haut L\u00e9v\u00eaque"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pierre-B\u00e9nite", 
                        "country": "France", 
                        "zip": "69495"
                    }, 
                    "name": "Centre Hospitalier Lyon-Sud"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rennes Cedex 9", 
                        "country": "France", 
                        "zip": "35033"
                    }, 
                    "name": "CHU Rennes - H\u00f4pital Pontchaillou"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St-Brieuc Cedex 1", 
                        "country": "France", 
                        "zip": "22000"
                    }, 
                    "name": "Centre Hospitalier Saint-Brieuc"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Strasbourg", 
                        "country": "France", 
                        "zip": "67000"
                    }, 
                    "name": "Strasbourg Oncologie Liberale"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse Cedex 9", 
                        "country": "France", 
                        "zip": "31059"
                    }, 
                    "name": "H\u00f4pital Purpan, CHRU Toulouse"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tours", 
                        "country": "France", 
                        "zip": "37044"
                    }, 
                    "name": "CHRU H\u00f4pital Bretonneau"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vandoeuvre Les Nancy Cedex", 
                        "country": "France", 
                        "zip": "54511"
                    }, 
                    "name": "CHU Nancy - H\u00f4pitaux Brabois"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Sebastian", 
                        "country": "Spain", 
                        "state": "Guipuzcoa", 
                        "zip": "20014"
                    }, 
                    "name": "Hospital de Donostia"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marbella", 
                        "country": "Spain", 
                        "state": "Malaga", 
                        "zip": "29603"
                    }, 
                    "name": "Hospital Costa del Sol"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "El Palmar", 
                        "country": "Spain", 
                        "state": "Murcia", 
                        "zip": "30120"
                    }, 
                    "name": "Hospital Virgen de la Arrixaca"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08036"
                    }, 
                    "name": "Hospital Clinic i Provincial"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08025"
                    }, 
                    "name": "Hospital Santa Creu i Sant Pau"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Granada", 
                        "country": "Spain", 
                        "zip": "18014"
                    }, 
                    "name": "Hospital Virgen de las Nieves"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28006"
                    }, 
                    "name": "Fundaci\u00f3n para la Investigaci\u00f3n Biomedica del Hospital La Princesa"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oviedo", 
                        "country": "Spain", 
                        "zip": "33006"
                    }, 
                    "name": "Hospital Central de Asturias"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pamplona", 
                        "country": "Spain", 
                        "zip": "31008"
                    }, 
                    "name": "Cl\u00ednica Universitaria de Navarra"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salamanca", 
                        "country": "Spain", 
                        "zip": "37007"
                    }, 
                    "name": "Hospital Salamanca"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santander", 
                        "country": "Spain", 
                        "zip": "39008"
                    }, 
                    "name": "Hospital Universitario Marqu\u00e9s de Valdecilla"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santiago de Compostela", 
                        "country": "Spain", 
                        "zip": "15706"
                    }, 
                    "name": "Hospital C.U.Santiago"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46026"
                    }, 
                    "name": "Hospital La F\u00e9"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zaragoza", 
                        "country": "Spain", 
                        "zip": "50012"
                    }, 
                    "name": "Hospital Quir\u00f3n La Floresta"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "France", 
                "Spain"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 3B, Randomized Trial of Lenalidomide Versus Placebo Maintenance Therapy Following Melphalan Prednisone Bortezomib Induction Therapy in Newly Diagnosed Multiple Myeloma", 
        "overall_contact": {
            "email": "clinicaltrialdisclosure@celgene.com", 
            "last_name": "Associate Director Clinical Trial Disclosure", 
            "phone": "1-888-260-1599"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Italy: The Italian Medicines Agency", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Progression-free survival (PFS) defined as the time from randomization to the first objective tumor progression according to International Myeloma Working Group (IMWG) criteria or death from any cause, whichever occurs first.", 
            "measure": "Progression Free Survival", 
            "safety_issue": "No", 
            "time_frame": "Approximately 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02112175"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "ORR (complete response [CR], very good partial response [VGPR] and partial response [PR]): during the maintenance phase, according to IMWG criteria.", 
                "measure": "Overall response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Approximately 3 years"
            }, 
            {
                "description": "PFS2: Time from randomization to objective tumor progression on next-line treatment or death from any cause, whichever occurs first.", 
                "measure": "Progression Free Survival 2 (PFS2)", 
                "safety_issue": "No", 
                "time_frame": "Approximately 6 years"
            }, 
            {
                "description": "OS defined as the time from the date of randomization to the date of death due to any cause", 
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "Approximately 6 years"
            }, 
            {
                "description": "Approximately 351 patients with AEs", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 6 years"
            }, 
            {
                "description": "QoL: Changes from baseline in overall scores and sub-scores using the European Organization for Research and Treatment of Cancer (EORTC) QoL Questionnaire for palliative care for Subjects with Cancer (EORTC QLQ-C15-PAL) Module, and the descriptive system of the EuroQoL 5-dimensions (EQ-5D)", 
                "measure": "Quality of Life (QoL)", 
                "safety_issue": "No", 
                "time_frame": "Approximately 3 years"
            }, 
            {
                "description": "Correlation of the qualitative description of bone marrow and peripheral blood morphology at baseline with the development of MDS/AML cases reported as SPMs", 
                "measure": "Cytomorphology", 
                "safety_issue": "No", 
                "time_frame": "Approximately 3 years"
            }, 
            {
                "description": "Correlation of Cumulative Illness Rating Scale (Geriatric version) of subjects at baseline to clinical outcomes", 
                "measure": "Comorbidity", 
                "safety_issue": "No", 
                "time_frame": "Approximately 3 years"
            }
        ], 
        "source": "Celgene Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}